title: Outcomes of transplantation with partial T-cell depletion of matched or mismatched unrelated or partially matched related donor bone marrow in children and adolescents with leukemias.
abstract: Graft-versus-host disease (GVHD) remains a major barrier to successful hematopoietic stem cell transplant for patients who lack a matched related donor. Partial T-cell depletion (TCD) of the graft may decrease the risk of severe GVHD with unrelated donors (URD) and partially matched related donors (PMRD) while retaining an antileukemic effect. We analyzed our experience using URD and PMRD for pediatric patients with leukemias from 1990 to 2001. A subgroup of 'matched' URD donor pairs was retrospectively analyzed for high-resolution class I. Partial TCD was accomplished with monoclonal antibody T10B9 or OKT3 and complement. There were 76 URD (45% matched) and 28 PMRD recipients. Event-free survival (EFS) was 38.3%, and overall survival (OS) 45.1% at 3 years. On multivariate analysis, there was no difference in survival based upon marrow source, but nonrelapse mortality was higher with the use of PMRD. Relapse occurred in 6% of ALL patients, and 22.8% of AML/MDS patients. Grades III-IV GVHD was observed in only 6.7% of patients. Partial TCD allows use of matched or mismatched URD, or PMRD with little mortality from GVHD, durable engraftment, and no increase in relapse risk.
authors.affiliation: Division of Oncology, The Children's Hospital of Philadelphia, 34th and Civic Center Blvd., Philadelphia, PA 19104, USA. buninn@email.chop.edu
authors.forename: N
authors.initials: N
authors.lastname: Bunin
authors.forename: R
authors.initials: R
authors.lastname: Aplenc
authors.forename: A
authors.initials: A
authors.lastname: Leahey
authors.forename: E
authors.initials: E
authors.lastname: Magira
authors.forename: S
authors.initials: S
authors.lastname: Grupp
authors.forename: G
authors.initials: G
authors.lastname: Pierson
authors.forename: D
authors.initials: D
authors.lastname: Monos
mesh_terms: D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D002648:Child; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000401:mortality / Q000517:prevention & control; D006648:Histocompatibility; D006650:Histocompatibility Testing / Q000379:methods; D006801:Humans; D007938:Leukemia / Q000401:mortality / Q000628:therapy*; D008212:Lymphocyte Depletion / Q000379:methods* / Q000401:mortality; D012008:Recurrence; D016019:Survival Analysis; D013601:T-Lymphocytes; D014019:Tissue Donors; D014181:Transplantation Immunology; D016896:Treatment Outcome